Application of ZBTB5 gene to detection and treatment of drug resistance of paclitaxel for cervical cancer

A technology for paclitaxel and cervical cancer, applied in the field of biomedicine, can solve problems such as treatment failure of patients with cervical squamous cell carcinoma, and achieve the effects of improving treatment effect, enhancing cell apoptosis, and inhibiting cell proliferation

Active Publication Date: 2021-08-13
BEIJING OBSTETRICS & GYNECOLOGY HOSPITAL CAPITAL MEDICAL UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, most patients will develop obvious drug resistance when treated with paclitaxel, and paclitaxel resistance is the main cause of treatment failure in patients with cervical squamous cell carcinoma.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ZBTB5 gene to detection and treatment of drug resistance of paclitaxel for cervical cancer
  • Application of ZBTB5 gene to detection and treatment of drug resistance of paclitaxel for cervical cancer
  • Application of ZBTB5 gene to detection and treatment of drug resistance of paclitaxel for cervical cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0035] (1) Screening paclitaxel resistance gene knockout targets in SiHa cells using in vitro cell models

[0036] 1. Screening of paclitaxel resistance genes in cervical cancer SiHa cells

[0037] CRISPR / Cas9 gene editing system was used to infect cervical cancer SiHa cells with lentivirus, and the candidate genes were screened after cultured with paclitaxel chemotherapy drug and DMSO solvent for 7 days and 14 days respectively.

[0038] Screening method:

[0039] High-throughput sequencing was performed on the cells of the paclitaxel chemotherapy drug group and the cells of the DMSO solvent group (the RNA sequence of the ZBTB5 gene transcript is SEQID NO: 2), and the fold change (FC) and Bayesian factor (BF) were selected to meet the following screening conditions genes as candidate genes.

[0040] Filter criteria:

[0041] FC≤-2 in the paclitaxel chemotherapy group, |FC|<2 in the DMSO solvent group;

[0042] And BF>2 in the paclitaxel chemotherapy group, BF<0 in the DMS...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of biological medicines, in particular to application of a ZBTB5 gene to detection and treatment of the drug resistance of paclitaxel for cervical cancer. The ZBTB5 gene is used as a marker for evaluating the drug resistance of a cervical cancer patient to the paclitaxel, a new detection target is provided for the drug resistance of the paclitaxel for cervical cancer, a provided detection product for the drug resistance of the paclitaxel for the cervical cancer can be used for evaluating the drug resistance condition of the cervical cancer patient to a paclitaxel drug in advance, and the treatment effect of the cervical cancer patient on the paclitaxel drug can be easily evaluated in advance. A ZBTB5 inhibitor is designed according to the ZBTB5 gene, the drug resistance of the cervical cancer patient on the paclitaxel can be reduced by inhibiting the ZBTB5 gene from playing the role or inhibiting the expression of the ZBTB5 gene, and the treatment effect of the paclitaxel on the cervical cancer can be improved through the combined action of the ZBTB5 inhibitor and the paclitaxel.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to the application of a ZBTB5 gene in the detection and treatment of paclitaxel resistance in cervical cancer. Background technique [0002] Cervical cancer is the fourth most common malignant tumor that endangers women's health worldwide, and 90% of cervical cancer patients suffer from cervical squamous cell carcinoma. According to statistics in 2018, there are 569,800 new cases of cervical cancer and 311,400 new deaths each year in the world. In underdeveloped countries, the survival rate of cervical cancer patients within 5 years is <50%, especially for stage III to IV cervical cancer. Cancer patients, the survival rate is only 5 to 15%, a serious threat to women's lives. [0003] In the clinical treatment plan for cervical cancer, paclitaxel is the first-line chemotherapy drug. Paclitaxel is a natural secondary metabolite extracted from the bark of Taxus chinensis. It ha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/6886C12N15/11A61K31/337A61K45/06A61P35/00
CPCC12Q1/6886A61K31/337A61K45/06A61P35/00C12Q2600/106
Inventor 吴玉梅何玥
Owner BEIJING OBSTETRICS & GYNECOLOGY HOSPITAL CAPITAL MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products